Nefiracetam ameliorates learning deficits in older rabbits and may act via the hippocampus

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 179-184

  Woodruff Pak, Diana S ^a,b  

^a POLISHER RESEARCH INSTITUTE   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

aging; Alzheimer's disease; CA1; cholinergic system; cognition enhancing; learning; memory; pyramidal cell

Indexed keywords

NEFIRACETAM;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; BRAIN INJURY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; LEARNING DISORDER; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031081262     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86065-2     Document Type: Conference Paper

References (39)

1. [1] Bahro, M., Schreurs, B.G., Sunderland, T. and Molchan, S.E., The effects of scopolamine, lorazepam and glycopyrrolate on classical conditioning of the human eyeblink response, Psychopharmacology, 122 (1996) 395-400.
2. [2] Berger, T.W., Long-term potentiation of hippocampal synaptic transmission affects rate of behavioral learning, Science, 224 (1984) 627-630.
3. [3] Bowen, D.M., Smith, C.B., White, P. and Davison, A.N., Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies, Brain, 99 (1976) 459-496.
4. [4] Coffin, J.M. and Woodruff-Pak, D.S., Delay classical conditioning in young and older rabbits: acquisition and retention at 12 and 18 months, Behav. Neurosci., 107 (1993) 63-71.
5. [5] Coyle, J.T., Price, D.L. and DeLong, M.R., Alzheimer's disease: a disorder of cortical cholinergic innervation, Science, 219 (1983) 1184-1190.
6. [6] Davies, P. and Maloney, A.J.F., Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, 2 (1976) 1403.
7. [7] Disterhoft, J.F., Coulter, D.A. and Alkon, D.L., Conditioning-specific membrane changes of rabbit hippocampal neurons measured in vitro, Proc. Natl. Acad. Sci USA, 83 (1986) 2733-2737.
8. [8] Flood, D.G. and Coleman, P.D., Neuron numbers and sizes in aging brain: comparisons of human, monkey, and rodent data, Neurobiol. Aging, 9 (1988) 453-463.
9. [10] Harvey, J.A., Gormezano, I. and Cool-Hauser, V.A., Effects of scopolamine and methylscopolamine on classical conditioning of the rabbit nictitating membrane response, J. Pharmacol. Exp. Ther., 225 (1983) 42-49.
10. [11] Hoehler, F.K. and Thompson, R.F., Effect of the interstimulus (CS-UCS) interval in hippocampal unit activity during classical conditioning of the nictitating membrane response of the rabbit (Oryctolagus cuniculus), J. Comp. Physiol. Psychol., 94 (1980) 201-215.
11. [12] Kowalska, M. and Disterhoft, J.F., Relation of nimodipine dose and serum concentration to learning enhancement in aging rabbits, Exp. Neurol., 127 (1994) 159-166.
12. [13] Moore, J.W., Goodell, N.A. and Solomon, P.R., Central cholinergic blockage by scopolamine and habituation, classical conditioning, and latent inhibition of rabbit's nictitating membrane response, Physiol. Psychol., 4 (1976) 395-399.
13. [14] Moyer, J.R. and Disterhoft, J.D., Increased calcium action potentials in aging rabbit CA1 neurons are reduced by low concentrations of nimodipine, Hippocampus, 4 (1994) 11-18.
14. [15] Moyer, J.R., Thompson, L.F., Black and Disterhoft, J.F., Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age- and concentration-dependent manner, J. Neurophysiol., 68 (1992) 2100-2109.
15. [16] Nabeshima, T., Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction, Drugs Today, 30 (1994) 357-379.
16. [17] Nakamura, J., Higashi, H., Nishi, S. and Nakazawa, Y., DM-9384, a pyrrolidone derivative, protects the membrane dysfunction induced by deprivation of oxygen and glucose in guinea-pig hippocampal neurons in vitro, Biol. Psychiatry, Suppl. 11, 29 (1991) Abstr. P-29-36.
17. [18] Schmaltz, L.W. and Theios, J., Acquisition and extinction of a classically conditioned response in hippocampectomized rabbits (Oryctologaus cuniculus), J. Comp. Physiol. Psychol., 79 (1972) 328-333.
18. [19] Solomon, P.R., Temporal versus spatial information processing theories of hippocampal function, Psychol. Bull., 86 (1979) 1272-1279.
19. [20] Solomon, P.R., Groccia-Ellison, M., Flynn, D., Mirak, J., Edwards, K.R., Dunehew, A. and Stanton, M.E., Disruption of human eyeblink conditioning after central cholinergic blockade with scopolamine, Behav. Neurosci., 107 (1993) 271-279.
20. [21] Solomon, P.R., Levine, E., Bein, T. and Pendlebury, W.W., Disruption of classical conditioning in patients with Alzheimer's disease, Neurobiol. Aging, 12 (1991) 283-287.
21. [22] Solomon, P.R. and Moore, J.W., Latent inhibition and stimulus generalization of the classically conditioned nictitating membrane response in rabbits (Oryctolagus cuniculus) following dorsal hippocampal ablations, J. Comp. Physiol. Psychol., 89 (1975) 1192-1203.
22. [23] Solomon, P.R., Solomon, S.D., Vander Schaaf, E. and Perry, H.E., Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure, Science, 220 (1983) 329-331.
23. [24] Sudo, K., Hashimoto, K., Fujimaki, Y. and Tachizawa, H., Disposition and metabolism of DM-9384, a cyclic GABA derivative, in the rat, dog, and monkey, Psychopharmacology, 96 (Suppl.) (1988) Abstr. 32.02.05.
24. [25] Thase, M.E., The relationship between Down syndrome and Alzheimer's disease. In: L. Nadel (Ed.), The Psychobiology of Down Syndrome, MIT Press, Cambridge, MA, 1987, pp. 345-368.
25. [26] Thompson, L.T., Deyo, R.A. and Disterhoft, J.F., Nimodipine enhances spontaneous activity of hippocampal pyramidal neurons in aging rabbits at a dose that facilitates associative learning, Brain Res., 535 (1990) 119-130.
26. [27] Thompson, L.T., Moyer, J.R., Jr., Black, J. and Disterhoft, J.F., Cellular mechanisms for nimodipine's reduction of aging-related learning deficits. In: E.M. Meyer (Ed.), Treatment of Dementias, Plenum Press, New York, 1992, pp. 241-256.
27. [28] Thompson, R.F., The neurobiology of learning, Science, 233 (1986) 941-947.
28. [29] Watabe S., Yamaguchi, H. and Ashida, S., DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex, Eur. J. Pharmacol., 238 (1993) 303-309.
29. [30] Wisniewski, K.E., Wisniewski, H.M. and Wen, G.Y., Alzheimer's disease in Down's syndrome, Ann. Neurol., 17 (1985) 278-282.
30. [31] Woodruff-Pak, D.S., Coffin, J.M. and Sasse, D.K., Learning, memory, and aging: neural changes and drug actions. In K.W. Schaie (Ed.), Annu. Rev. Gerontol. Geriatr., Vol. 11, Springer, New York, 1991, pp. 23-54.
31. [32] Woodruff-Pak, D.S., Finkbiner, R.G. and Katz, I.R., A model system demonstrating parallels in animal and human aging: extension to Alzheimer's disease. In: E.M. Meyer, J.W. Simpkins and J. Yamamoto (Eds.), Novel Approaches to the Treatment of Alzheimer's Disease, Plenum, New York, 1989, pp. 355-371.
32. [33] Woodruff-Pak, D.S., Finkbiner, R.G. and Sasse, D.K., Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged, NeuroReport, 1 (1990) 45-48.
33. [34] Woodruff-Pak, D.S., Lavond, D.G., Logan, C.G. and Thompson, R.F., Classical conditioning in 3-, 30-, and 45 month-old rabbits: behavioral learning and hippocampal unit activity, Neurobiol. Aging, 8 (1987) 101-108.
34. [35] Woodruff-Pak, D.S. and Li, Y.-T., Nefiracetam (DM-9384): effect on classical conditioning in older rabbits, Psychopharmacology, 114 (1994) 200-208.
35. [36] Woodruff-Pak, D.S., Li, Y.-T., Kazmi, A. and Kem, W.R., Nicotinic cholinergic system involvement in eyeblink classical conditioning in rabbits, Behav. Neurosci., 108 (1994) 486-493.
36. [37] Woodruff-Pak, D.S. and Papka, M., Alzheimer's disease and eyeblink conditioning: 750 ms trace vs. 400 ms delay paradigm, Neurobiol. Aging, 17 (1996) 397-404.
37. [38] Woodruff-Pak, D.S., Papka, M. and Simon, E.W., Eyeblink classical conditioning in Down's syndrome, fragile X syndrome, and normal adults over and under age 35, Neuropsychology, 8 (1994) 14-24.
38. [39] Woodruff-Pak, D.S., Papka, M., Romano, S. and Li, Y.-T., Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia, Neurobiol. Aging, in press.
39. [40] Yoshi, M. and Watabe, S., Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells, Brain Res., 642 (1994) 123-131.